Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT03138889. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without chemotherapy. The study is comprised of two groups; dose optimization and dose expansion cohorts. Dose Optimization included first-line and second-line advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) The dose expansion cohort will include first-line NSCLC patients.
Study identification
- NCT ID
- NCT03138889
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 162 participants
Conditions and interventions
Conditions
Interventions
- NKTR-214 Drug
- Pembrolizumab Drug
- Cisplatin Drug
- Carboplatin Drug
- Nab paclitaxel Drug
- Paclitaxel Drug
- Pemetrexed Drug
- Atezolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2017
- Primary completion
- Jul 4, 2022
- Completion
- Aug 23, 2022
- Last update posted
- Mar 9, 2023
2017 – 2022
United States locations
- U.S. sites
- 23
- U.S. states
- 20
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group, PA - North Hills | Fayetteville | Arkansas | 72703 | — |
| California Pacific Medical Center | San Francisco | California | 94115 | — |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| Augusta University - Augusta University Medical Center | Augusta | Georgia | 30912 | — |
| Ochsner Medical Center | New Orleans | Louisiana | 70816 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Park Nicollet - Frauenshuh Cancer Center | Saint Louis Park | Minnesota | 55426 | — |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63156 | — |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59101 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley | Las Vegas | Nevada | 89169 | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| New York University Langone Medical Center | New York | New York | 10016 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Duke Clinical Research Institute | Durham | North Carolina | 27705 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| West Cancer Center | Germantown | Tennessee | 38138 | — |
| Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium) | Nashville | Tennessee | 37203 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Inova Melanoma and Skin Cancer Center | Fairfax | Virginia | 22031 | — |
| Blue Ridge Cancer Care | Roanoke | Virginia | 24153 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
| Froedtert & the Medical College of Wisconsin Froedtert Hospital | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
Recently updated Non-Small Cell Lung Cancer trials
Other public records listing Non-Small Cell Lung Cancer. Sorted by last update posted; newest first. Not a recommendation.
- NCT07777822: Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC Recruiting
- NCT07770100: Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) Not yet recruiting
- NCT07761910: Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Recruiting
- NCT07541170: A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) Recruiting
- NCT06448754: Volrustomig Priming Regimens Exploratory Phase II Platform Study Recruiting
- NCT07412041: Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03138889, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 9, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03138889 live on ClinicalTrials.gov.